Hirokazu Shoji

Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Metastatic Colorectal Cancer

Top Venues

Cancer medicine

Journal of cancer research and clinical oncology

Future science OA

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D Danenberg, Narikazu Boku, Takako Eguchi Nakajima
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID). Cancer medicine 13 (7) (2024)
Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D Danenberg, Narikazu Boku, Takako Eguchi Nakajima
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID). Cancer medicine 13 (7) (2024)
Toru Kadono, Satoru Iwasa, Toshiharu Hirose, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Atsuo Takashima, Ken Kato
Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real-world analysis. Cancer medicine 13 (12) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Toru Kadono, Satoru Iwasa, Toshiharu Hirose, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Atsuo Takashima, Ken Kato
Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real-world analysis. Cancer medicine 13 (12) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Toru Kadono, Satoru Iwasa, Toshiharu Hirose, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Atsuo Takashima, Ken Kato
Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real-world analysis. Cancer medicine 13 (12) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Yuri Yoshinami, Hirokazu Shoji
Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. Future science OA 9 (2) (2023)
Hirokazu Shoji, Daisuke Takahari, Hiroki Hara, Kengo Nagashima, Jun Adachi, Narikazu Boku
A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811). Future science OA 7 (7) (2021)
Yoshitaka Honma, Kengo Nagashima, Hidekazu Hirano, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Natsuko Okita, Ken Kato, Narikazu Boku, Naoya Murakami, Kouji Inaba, Yoshinori Ito, Jun Itami, Jun Kanamori, Junya Oguma, Hiroyuki Daiko
Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. Cancer medicine 9 (2) (2019)
Kaoru Onidani, Hirokazu Shoji, Takahiko Kakizaki, Seiichi Yoshimoto, Shinobu Okaya, Nami Miura, Shoichi Sekikawa, Koh Furuta, Chwee Teck Lim, Takahiko Shibahara, Narikazu Boku, Ken Kato, Kazufumi Honda
Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA. Cancer science 110 (8) (2019)